Canopy Biosciences Acquires Core Diagnostics

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

HCAP Partners' IDS Acquires Core Analytics Lab & Radiology

January 15, 2026

Healthcare Services

HCAP Partners completed a follow-on, add-on acquisition for its Integrated Diagnostic Services (IDS) platform with the purchase of Core Analytics Lab & Radiology, a provider of mobile radiology and laboratory services across California. The deal expands IDS' footprint into Northern California, adds in-house mobile laboratory diagnostics to its bundled service offering for skilled nursing, long-term care, and home health providers, and increases statewide route density and service integration.

Integrated Diagnostic Services Acquires Core Analytics Lab & Radiology with Backing from St. Cloud Capital

January 15, 2026

Healthcare Services

St. Cloud Capital made a growth capital investment in Integrated Diagnostic Services (IDS) to support IDS’ acquisition of Core Analytics Lab & Radiology, a provider of mobile radiology and laboratory services in California. The financing round included participation from HCAP Partners, Southfield Mezzanine, and California Bank & Trust and is intended to expand IDS’ in‑house lab capabilities, improve route density, and increase responsiveness to patients in post‑acute settings.

Canopy Biosciences Acquires Zellkraftwerk GmbH

April 29, 2019

Biotechnology

Canopy Biosciences acquired Leipzig-based Zellkraftwerk GmbH, adding Zellkraftwerk’s ChipCytometry multiplex cytometry instruments and related services to Canopy’s multi-omics portfolio. Concurrently, Ampersand Capital Partners made a strategic growth investment in Canopy to support geographic expansion and product/service scale-up across the US, Europe and Asia.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

LabGenomics USA Acquires Integrated Molecular Diagnostics (IMD) CLIA Labs

October 25, 2024

Healthcare Services

LabGenomics USA acquired Integrated Molecular Diagnostics (IMD) CLIA labs, expanding its U.S. footprint to four CLIA-certified laboratories and strengthening its molecular and oncology diagnostic capabilities. The deal broadens LabGenomics' geographic reach across the U.S. coasts and positions the company to launch new laboratory-developed tests (LDTs) and expand reimbursable services.